Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

NCT04324164 · tracked via the Priya Life Science China tracker

Sponsor

Hunan Province Tumor Hospital

Phase

Observational

Started

2020-03-24

Last updated

2025-01-27

Condition(s) studied

Non-small Cell Lung Cancer

Investigational drug(s) / intervention(s)

Third-generation EGFR-TKIEGFR-TKI

Third-generation EGFR-TKI: Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.

EGFR-TKI: All EGFR-TKI

Study summary

This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * 18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * Uncommon EGFR Mutant Advanced NSCLC Exclusion Criteria: * Patients with contraindication of chemotherapy * Pregnant or breast feeding women

Primary outcome measure(s)

PFS — 5 years
Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)

Trial sites (1)

Facility	City	Region	Status
Yongchang Zhang	Changsha	Hunan	Recruiting

More Hunan Province Tumor Hospital trials in China

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK Recruiting

Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement Recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC Recruiting

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases Recruiting

Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy Recruiting

Other trials for the same condition

Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors Recruiting

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer Active, not recruiting

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors Recruiting

Myeloprotection With Trilaciclib in Pan-cancer Population Starting soon

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04324164 on ClinicalTrials.gov ↗ ← All trials in China